摘要: |
目的:分析树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)免疫治疗联合化疗在晚期肺癌中的效果以及对患者肿瘤标志物、生存周期的影响。方法:回顾性分析我院2020年1月至2021年1月收治的83例晚期肺癌患者临床资料,根据其治疗方法将患者分为联合组40例与化疗组43例,联合组采用DC-CIK免疫治疗联合化疗,化疗组进行化疗,对比两组临床疗效,肿瘤标志物癌胚抗原(CEA)、细胞角蛋白19片段(Cyfra21-1)水平,免疫功能指标CD3+、CD4+、自然杀伤细胞(NK)水平,血清微小RNA(miR)-137、miR-155水平以及患者生存周期。结果:联合组客观有效率(ORR)、疾病控制率(DCR)与化疗组比较均无显著差异(P>0.05)。治疗后,两组CEA、Cyfra21-1水平均降低(P<0.05),且联合组CEA、Cyfra21-1水平低于化疗组(P<0.05)。治疗后,联合组CD3+、CD4+、NK细胞水平均升高(P<0.05),且联合组CD3+、CD4+、NK细胞水平均高于化疗组(P<0.05)。治疗后,两组miR-137、miR-155水平均降低(P<0.05),且联合组miR-137、miR-155水平低于化疗组(P<0.05)。两组各不良反应发生率比较均无显著差异(P>0.05)。联合组无进展生存期(PFS)、总生存期(OS)均长于化疗组(P<0.05)。结论:DC-CIK免疫治疗联合化疗能够降低晚期肺癌患者肿瘤标志物CEA、Cyfra21-1水平及血清miR-137、miR-155水平,改善其免疫功能,延长患者生存周期。 |
关键词: 晚期肺癌 树突状细胞-细胞因子诱导的杀伤细胞 肿瘤标志物 免疫功能 生存周期 |
DOI: |
分类号: |
基金项目:苏州科技局 |
|
Efficacy of DC-CIK immunotherapy combined with chemotherapy in advanced lung cancer and the effect on patients" serum miR-137 and miR-155 |
hubowen, dulingyu
|
The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University
|
Abstract: |
To analyze the effect of dendritic cell-cytokine-induced killer cell (DC-CIK) immunotherapy combined with chemotherapy in advanced lung cancer and its effects on patient tumor markers and survival cycle.Methods: Retrospective analysis of the clinical data of 83 patients with advanced lung cancer from January 2020 to January 2021, according to their treatment method, the patients were divided into combination group and 43 patients in chemotherapy group, DC-CIK immunotherapy combined chemotherapy and chemotherapy group underwent chemotherapy.Compared with the clinical efficacy, the levels of the tumor marker cancer embryo antigen (CEA), the cytokeratin 19 fragment (Cyfra21-1), the immune function indicators CD3 +, CD4 +, natural killer cells (NK) levels, and the patient survival cycle of the two groups.Results: There were no significant difference between objective efficiency (ORR), disease control rate (DCR) and the chemotherapy group (P> 0.05).After treatment, the levels of CEA and Cyfra21-1 were reduced in both groups (P <0.05), and in the combined group, the CEA and Cyfra21-1 levels were lower than in the chemotherapy group (P <0.05).After treatment, the levels of CD3 +, CD4 +, and NK cells were increased in the combination group (P <0.05), and the levels of CD3 +, CD4 +, and NK cells were higher than in the chemotherapy group (P <0.05).After treatment, the levels of miR-137 and miR-155 were decreased in both groups (P <0.05), and in the combined group, the miR-137 and miR-155 levels were lower than in the chemotherapy group (P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05).The combined progression-free survival (PFS) and overall survival (OS) were longer than in the chemotherapy group (P <0.05).Conclusions: DC-CIK immunotherapy combined with chemotherapy can reduce the levels of CEA, Cyfra21-1, the tumor markers in advanced lung cancer patients, improve their immune function, and prolong the survival cycle of patients. |
Key words: Advanced lung cancer Dendritic cell-cytokine-induced killer cells Tumor markers Immune function Survival cycle |